



Level 17, 201 Miller St
North Sydney
NSW 2060 Australia
Ph: +61 2 8923 2512
Fax: +61 2 8923 2525

1/112 Ferrier Avenue
Toronto, Ontario
M4K 3H4 Canada
Ph: +1 416 465 8545
Fax: +1 416 465 0350

www.ritract.com
abc: 28 106 353 253

14 June 2005

Clinical evaluation trial underway.

Ritract Limited is pleased to advise that the clinical evaluation trial of the Company's safety syringe commenced at St Vincents Hospital, Sydney last week.

Nursing staff at the Hospital have commenced use of the syringe on selected patient wards after receiving in service support and training provided by specialist representatives from Ritract's Australian distributor, Device Technologies.

St Vincents Hospital was chosen as the preferred evaluation site because it is well recognized as being a leading institution for infection control initiatives and evaluation of new medical technologies.

Ritract Limited Managing Director, Rupert Northcott, said "this trial is an important opportunity for the Company to assess market acceptance of our syringe. We have received very encouraging anecdotal reports about the syringe from various healthcare professionals globally who have advised us it is one of the best safety syringes available. We are confident that in putting our product to the test in the demanding hospital environment these initial reactions will be confirmed."

"Ritract's product offers significant benefits over the first generation of automatic retractable syringes and other safety injection devices. We expect that over the next few weeks hospital staff will recognise and appreciate the benefits provided by the Ritract syringe and make it their preferred choice safety product," he added.

A number of other leading hospitals and clinics have expressed interest in evaluating the Ritract syringe and we expect to announce the commencement of trials by these parties shortly.

For further information please contact Rupert Northcott or John Bell on 02 8923 2518

About Ritract

Ritract Limited listed on the ASX on 18th December 2003 (ASX:RTL). Ritract is a medical devices company with patented products and technologies to meet the growing world demand for safety injection solutions. Ritract's mission is to develop and market innovative, patented products and technologies that are safe, effective and affordable. To this end, Ritract has aggressively pursued the development of retractable, auto-disable safety syringe technology and has acquired the Needlesleeve safety needle technology to create a range of safety products designed to eliminate needlestick injuries from the healthcare workplace.